|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
90,000,000 |
Market
Cap: |
1.70(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$18.88 - $18.88 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Schatzman Randall C |
President and CEO |
|
2016-04-15 |
4 |
AS |
$28.11 |
$394,150 |
D/D |
(14,024) |
112,947 |
|
- |
|
Schatzman Randall C |
President and CEO |
|
2016-04-15 |
4 |
OE |
$0.39 |
$10,227 |
D/D |
14,024 |
126,971 |
|
- |
|
Schatzman Randall C |
President and CEO |
|
2016-04-14 |
4 |
AS |
$28.01 |
$321,075 |
D/D |
(11,462) |
112,947 |
|
- |
|
Schatzman Randall C |
President and CEO |
|
2016-04-14 |
4 |
OE |
$0.39 |
$4,413 |
D/D |
11,462 |
124,409 |
|
- |
|
Litton Mark James |
Chief Business Officer |
|
2016-01-04 |
4 |
AS |
$31.19 |
$784,951 |
D/D |
(25,000) |
73,718 |
|
- |
|
Litton Mark James |
Chief Business Officer |
|
2016-01-04 |
4 |
OE |
$0.39 |
$9,625 |
D/D |
25,000 |
98,718 |
|
- |
|
Latham John A |
Chief Scientific Officer |
|
2016-01-04 |
4 |
AS |
$31.09 |
$314,137 |
D/D |
(10,000) |
241,726 |
|
- |
|
Latham John A |
Chief Scientific Officer |
|
2016-01-04 |
4 |
OE |
$1.27 |
$12,650 |
D/D |
10,000 |
251,726 |
|
- |
|
Schatzman Randall C |
President and CEO |
|
2016-01-04 |
4 |
AS |
$31.35 |
$314,747 |
D/D |
(10,000) |
111,579 |
|
- |
|
Schatzman Randall C |
President and CEO |
|
2016-01-04 |
4 |
OE |
$0.39 |
$3,850 |
D/D |
10,000 |
121,579 |
|
- |
|
Schatzman Randall C |
President and CEO |
|
2015-12-01 |
4 |
AS |
$37.24 |
$372,431 |
D/D |
(10,000) |
111,579 |
|
- |
|
Schatzman Randall C |
President and CEO |
|
2015-12-01 |
4 |
OE |
$0.39 |
$3,850 |
D/D |
10,000 |
121,579 |
|
- |
|
Smith Jeffrey T L |
Sr. VP Translational Medicine |
|
2015-12-01 |
4 |
AS |
$37.24 |
$159,104 |
D/D |
(4,272) |
0 |
|
- |
|
Smith Jeffrey T L |
Sr. VP Translational Medicine |
|
2015-12-01 |
4 |
OE |
$0.39 |
$1,645 |
D/D |
4,272 |
4,272 |
|
- |
|
Latham John A |
Chief Scientific Officer |
|
2015-12-01 |
4 |
AS |
$37.24 |
$169,452 |
D/D |
(4,550) |
241,726 |
|
- |
|
Latham John A |
Chief Scientific Officer |
|
2015-12-01 |
4 |
OE |
$0.39 |
$1,752 |
D/D |
4,550 |
246,276 |
|
- |
|
Benedict Larry |
Sr. VP Finance |
|
2015-11-30 |
4 |
A |
$8.50 |
$17,000 |
D/D |
2,000 |
28,247 |
|
- |
|
Dow Stephen M |
Director |
|
2015-11-30 |
4 |
S |
$37.11 |
$3,266 |
I/I |
(88) |
0 |
|
- |
|
Latham John A |
Chief Scientific Officer |
|
2015-11-02 |
4 |
AS |
$32.68 |
$153,137 |
D/D |
(4,545) |
241,265 |
|
- |
|
Latham John A |
Chief Scientific Officer |
|
2015-11-02 |
4 |
OE |
$0.39 |
$1,750 |
D/D |
4,545 |
245,810 |
|
- |
|
Schatzman Randall C |
President and CEO |
|
2015-11-02 |
4 |
AS |
$32.70 |
$337,066 |
D/D |
(10,000) |
109,921 |
|
- |
|
Schatzman Randall C |
President and CEO |
|
2015-11-02 |
4 |
OE |
$0.39 |
$3,850 |
D/D |
10,000 |
119,921 |
|
- |
|
Smith Jeffrey T L |
Sr. VP Translational Medicine |
|
2015-11-02 |
4 |
AS |
$32.70 |
$131,299 |
D/D |
(3,900) |
0 |
|
- |
|
Smith Jeffrey T L |
Sr. VP Translational Medicine |
|
2015-11-02 |
4 |
OE |
$0.39 |
$1,502 |
D/D |
3,900 |
3,900 |
|
- |
|
Bridger Gary |
Director |
|
2015-10-31 |
4 |
D |
$0.00 |
$0 |
I/I |
(3,469,528) |
0 |
|
- |
|
296 Records found
|
|
Page 7 of 12 |
|
|